← back to search

Sara Balduzzi

University of Fribourg ·
Area of research
Cancer Research · Oncology
Research interest
Research interests include Medicine, Internal medicine, Breast cancer, Oncology, Trastuzumab, and COPD.
h-index
citations
1,469
works
20
NIH funding
primary concept
email

Recent publications

Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial
Nature Medicine 2026cited by 3position: middledoi
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early <i>ERBB2</i>-Positive Breast Cancer
JAMA Oncology 2025cited by 15position: middledoi
Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials: a meta-epidemiological study
Cochrane Database of Systematic Reviews 2024cited by 54position: middledoi
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy
JAMA Oncology 2024cited by 44position: middledoi
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial
Journal of Clinical Oncology 2023cited by 25position: middledoi
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer
JNCI Journal of the National Cancer Institute 2023cited by 13position: middledoi
Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial.
Journal of Clinical Oncology 2022cited by 2position: middledoi
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
Annals of Oncology 2019cited by 96position: middledoi
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
BMC Medicine 2019cited by 25position: middledoi
PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.
Journal of Clinical Oncology 2019cited by 8position: middledoi
American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients
Blood Advances 2018cited by 799position: middledoi
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
Annals of Oncology 2018cited by 154position: middledoi
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.
Journal of Clinical Oncology 2017cited by 36position: middledoi
LATE-BREAKING ABSTRACT: Risk factors for hospitalization and death in elderly smokers with chronic obstructive pulmonary disease (COPD) and/or chronic heart failure (CHF)
2016cited by 0position: middledoi
Chronic obstructive pulmonary disease assessment test (CAT) in patients with COPD, chronic heart failure (CHF), and both
2016cited by 0position: middledoi
Antibiotic Treatment of Severe Exacerbations of Chronic Obstructive Pulmonary Disease with Procalcitonin: A Randomized Noninferiority Trial
PLoS ONE 2015cited by 51position: middledoi
The TRIBECA study: (TRI)fecta (B)ioprosthesis (E)valuation versus (C)arpentier Magna-Ease in (A)ortic position
European Journal of Cardio-Thoracic Surgery 2015cited by 51position: middledoi
Comorbidities in elderly smokers with COPD or CHF
2015cited by 0position: middledoi
Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study
PLoS ONE 2013cited by 24position: middledoi
Herbal supplements in pregnancy: unexpected results from a multicentre study
Human Reproduction 2012cited by 69position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Roberto D’Amico · University of Modena and Reggio Emilia7 papers (2015–2025)Valentina Guarneri · Mario Negri Institute for Pharmacological Research7 papers (2017–2025)Pierfranco Conté · Candiolo Cancer Institute7 papers (2017–2025)Giancarlo Bisagni · Azienda Sanitaria Unità Locale di Reggio Emilia6 papers (2017–2025)Bianca Beghé · University of Ferrara5 papers (2013–2016)Antonino Musolino · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori5 papers (2017–2025)Antonio Frassoldati · University of Ferrara5 papers (2017–2023) · 5 papers (2017–2025)Alessia Verduri · Cardiff University5 papers (2013–2016)Maria Vittoria Dieci · Burning Rock Biotech (China)5 papers (2019–2023)Federico Piacentini · Ospedale Santa Chiara5 papers (2017–2025)Ornella Garrone · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico5 papers (2017–2025)Leonardo M. Fabbri · University of Ferrara5 papers (2013–2016) · 4 papers (2015–2023)Alba A. Brandes · AstraZeneca (Italy)4 papers (2017–2022) · 4 papers (2019–2025)Federica Miglietta · University of Bari Aldo Moro4 papers (2019–2025)Enrico Orvieto · University of Padua3 papers (2019–2025)Michela Schito · University of Ferrara3 papers (2015–2016)Luigi Cavanna · Amgen (United States)3 papers (2019–2025)